Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | UV Flu Technologies Highlights 2010 Operations, ViraTech UV-400 is Selected as Product of Choice byUV Flu Technologies, Inc. manufacturers of innovative air purification technology announced today that the Company has been informed by one of its distributors, INE Global, of Boston, Mass, that “Clean Air for Everyone,”
By: InvestorIdeas “This product can help our schools, and the children within them,” said John Pappas, spokesperson for ‘Clean Air for Everyone.’ “There are thousands of schools, homeless shelters, and Aids clinics around the country, that suffer through horrific air quality, due to the lack of funding to correct or improve the situation. The UV-400 kills the bacteria, odors, VOCs, and other organic contaminants that cause sickness, respiratory problems, and allergies that make our children ill.” The announcement of this news now positions UV Flu Technologies across a multitude of operational initiatives and industry segments including: Sports and Athletics – Announced an order of UV-400 units in the locker room of the renowned Boston Bruins hockey team. "This is the second professional hockey team to put the UV-400 in their locker rooms, along with numerous colleges," noted Charles Gulteri President of New England Sports Sales (NESSI). “This could be one of the most important developments to college and professional sports in the last 20 years.” Healthcare and Medical – Units have been utilized in 2 major hospitals, and are currently being evaluated by a major nursing home chain. Units placed with the prestigious Miami Anatomical Research Center featuring 40 state-of-the art bio-skill lab stations in a hospital style setting. Hospitality, Hotel & Spa - The Seagate Hotel and Spa in Delray Beach, Florida, the Boston Harbor Hotel, and Boston’s XV Beacon Hotel utilize the ViraTech UV-400. “Providing this extra level of protection sets us apart from the competition," European Market – Profiled in two editions (July and October) of the prestigious UK industry opinion and analysis publication “The Public Service Review” featuring the latest initiatives and projects on best practices affecting public sector initiatives worldwide. This announcement was followed almost immediately by a sales order with Paris based, Societe Nema Citizen, the largest distributor of Citizen Brand electronics in France, and a growing inventory of health and medical-related products sold throughout Western Europe. Restaurants - The ViraTech UV-400 is undergoing testing supervised by one of the largest hotel and restaurant suppliers in the Northeast. The unit is being evaluated in the lounge, dining, and food prep areas of 3 notable NYC restaurants. The product’s ability to reduce odors, VOCs, while killing bacteria and other contaminants, is drawing considerable attention in this segment. National Distribution Network – The Company added 3 new distributors including Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area. New Research - Received favorable preliminary test results from independent FDA and EPA certified test facilities that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol. If advanced stage testing proves positive, this could be a momentous step forward in the further development of the product as a Medical Device. Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) About UV Flu Technologies, Inc. UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product has also been proven to reduce the concentration of odors and Volatile Organic Compounds in independent lab tests. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information visit: www.uvflutech.com. Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. ON BEHALF OF THE BOARD UV Flu Technologies, Inc. John J. Lennon, President & CEO Investor Information: investors@uvflutech.com www.uvflutech.com Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising. Investorideas.com Disclaimer: http://www.investorideas.com/ Investorideas.com Disclosure: http://www.investorideas.com/ # # # InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including energy and mining stocks, addition to global markets including China, India and Australia. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
